Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Rigel Pharmaceuticals Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“McKesson Corporation 42% 45%”
$124M relationship
basisRIGL fy2025 · closed 2025-12 $294M
FILING10-K0001034842-26-000015cik 0001034842
“Cencora Inc. 19% 20%”
$56M relationship
basisRIGL fy2025 · closed 2025-12 $294M
FILING10-K0001034842-26-000015cik 0001034842
“Further, in February 2024, we entered into an Asset Purchase Agreement with Blueprint to purchase certain assets comprising the right to research, develop, manufacture and commercialize GAVRETO, Blueprint's proprietary RET inhibitor of tyrosine kinase for the treatment of metastatic RET fusion-positive NSCLC and advanced thyroid cancer, in the US.”
FILING10-K0001558370-25-002169cik 0001034842
“In July 2022, we entered into a license and transition services agreement with Forma for an exclusive license to develop, manufacture and commercialize olutasidenib, a proprietary inhibitor of mIDH1, for any uses worldwide, including for the treatment of AML and other malignancies.”
FILING10-K0001558370-25-002169cik 0001034842
“We have an Open Market Sale Agreement with Jefferies LLC (Jefferies) entered on August 4, 2020, and amended and restated on August 2, 2024, pursuant to which, we may sell from time to time, through Jefferies, shares of our common stock in sales deemed to be "at-the-market offerings" as defined in Rule 415 under the Securities Act, subject to conditions specified in the Open Market Sale Agreement, including maintaining an effective registration statement covering the sale of shares under the Open Market Sale Agreement.”
FILING10-K0001558370-25-002169cik 0001034842
“We entered into a Credit Agreement with MidCap on September 27, 2019, amended on March 29, 2021, February 11, 2022, July 27, 2022, and April 11, 2024.”
FILING10-K0001558370-25-002169cik 0001034842
“Under the collaboration, we will provide CONNECT with funding up to $3.0 million and study material over the four-year collaboration.”
FILING10-K0001034842-26-000015cik 0001034842
“Under the Strategic Collaboration Agreement, we will provide MDACC the study materials and $15.0 million in time-based milestone payments as compensation for services to be provided for the studies, over the five-year collaboration term, unless terminated earlier as provided for in the agreement.”
FILING10-K0001034842-26-000015cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“Government contracts revenue in 2023 comprised $1.0 million of government award granted to us by the US Department of Defense (DOD) to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients, and $0.1 million award granted to us by Biomedical Advanced Research and Development (BARDA), part of the Office of the Assistant Secretary for the Preparedness and Response at the DHHS for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress.”
FILING10-K0001558370-25-002169cik 0001034842
“Cardinal Health, Inc. * 13%”
FILING10-K0001034842-26-000015cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“We have received payments from our current collaborations including Lilly, Grifols, Kissei, Medison, Knight, BerGenBio, and Daiichi.”
FILING10-K0001558370-25-002169cik 0001034842
“Government contracts revenue in 2023 comprised $1.0 million of government award granted to us by the US Department of Defense (DOD) to support our Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients, and $0.1 million award granted to us by Biomedical Advanced Research and Development (BARDA), part of the Office of the Assistant Secretary for the Preparedness and Response at the DHHS for our evaluation of fostamatinib in mitigating the impact of long-term respiratory distress.”
FILING10-K0001558370-25-002169cik 0001034842
“We paid Lilly a total of $21.4 million for our share of development costs incurred through April 1, 2024.”
FILING10-K0001034842-26-000015cik 0001034842
“As of December 31, 2024, we have a contractual commitment related to our sublease agreement with Atara for approximately $0.3 million, payable through the expiration of the sublease agreement in May 2025.”
FILING10-K0001558370-25-002169cik 0001034842
“In addition, we recognized revenue from Grifols of $9.1 million related to delivery of drug supplies and earned royalty, and $4.0 million from Dr. Reddy's related to an upfront fee from sublicensing olutasidenib.”
FILING10-K0001558370-25-002169cik 0001034842
Watchlist prices, news filtered to it, and its next report on your desk.
Rigel Pharmaceuticals Inc has 8 disclosed suppliers and 13 disclosed customers. Each one is named in an SEC filing, either Rigel Pharmaceuticals Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
RIGL (Rigel Pharmaceuticals Inc) has 8 disclosed suppliers and 13 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.